Company News: iOmx Therapeutics raises EUR 40 million in Series A round

– Company establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, today announced the closing of a Series A financing round totaling EUR 40 million. MPM Capital and Sofinnova Partners co-led the round, and were joined by Wellington Partners and Merck Ventures.

iOmx focuses on the development of first-in-class cancer therapeutics addressing next-generation immune checkpoints. By systematically screening human tumor cells, the company has already identified a number of new targets and analyzed their mode of action. The proceeds of the financing round will be used to advance several proprietary product candidates up to initial clinical proof-of-concept.

iOmx was founded based on work from the laboratory of oncology expert and co-founder Philipp Beckhove, previously at the German Cancer Research Center, Heidelberg, and now at the RCI Regensburg Center for Interventional Immunology. The company’s innovative screening platform was developed by co-founder Nisit Khandelwal, SVP of Research. Additional co-founders include highly experienced biotech executives and internationally renowned cancer specialists Patrick Baeuerle, Elmar Maier (CBO), and Sebastian Meier-Ewert (CEO).

“The development of checkpoint inhibitors represents a major advance in the treatment of certain cancers. However, despite some truly transformative successes, to date only a minority of patients benefit from existing treatment options. We aim to bring the advances in immuno-oncology to a greater proportion of cancer patients,” said Sebastian Meier-Ewert, CEO of iOmx. “Therefore, we are proud to have attracted such an outstanding international investor base. The round was significantly oversubscribed, highlighting the expectation that immune checkpoint-based cancer therapeutics have great potential for changing the oncology landscape – and iOmx is excellently positioned to play a leading role in this field.”

“We are thrilled to back iOmx, together with such a high profile investor syndicate. The company combines all the key features we are looking for when investing: an exceptional management team, world class science, and a market breaking technology platform that has the potential to build a strong pipeline of proprietary and more efficacious cancer therapeutics,” said Henrijette Richter, Chairwoman of iOmx´ Board of Directors and Partner at Sofinnova Partners.